Lenalidomide
Revlimid · Immunomodulator · Cereblon (CRBN)
Cereblon-binding immunomodulatory drug. Enhances immune surveillance, direct anti-tumor effects, and anti-angiogenic activity.
Relapsed/refractory MCL; frontline chemo-free with rituximab
Andre Goy
Chairman and Executive Director, John Theurer Cancer Center · Hackensack Meridian Health
Jia Ruan
Professor of Clinical Medicine · Weill Cornell Medicine
John Leonard
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology · Weill Cornell Medicine
Marco Ladetto
Associate Professor of Hematology, President of FIL · University of Eastern Piedmont / Azienda Ospedaliera SS Antonio e Biagio
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.
Blood advances · Feb 2026
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.
Blood advances · Jan 2026
Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma.
Blood advances · Sep 2025
Real-World Treatment Patterns and Out-of-Pocket Costs After CAR T-Cell Therapy in Commercially Insured Patients With B-Cell Non-Hodgkin Lymphoma in the United States.
Transplantation and cellular therapy · Sep 2025
Real-World Efficacy and Safety of the Combination of Rituximab, Lenalidomide, and Ibrutinib in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · Jul 2025
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial.
Blood advances · Apr 2025
Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial.
HemaSphere · Mar 2025
Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States.
Journal of managed care & specialty pharmacy · Mar 2025
Jerkeman M, Kolstad A, Hutchings M, et al. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood Adv. 2024;8(2):407-415.
Blood advances · Oct 2024
Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi.
British journal of haematology · Oct 2024
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis.
Clinical lymphoma, myeloma & leukemia · Oct 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Blood · Sep 2024
Dismantling relapsed/refractory mantle cell lymphoma.
Blood reviews · Sep 2024
Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma.
Discover oncology · Apr 2024
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica · Apr 2024
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
Blood advances · Jan 2024